NeuSoft(600718) 证券时报网·2024-11-11 10:03Core Viewpoint - Neusoft Group reported a revenue of 6.891 billion yuan for the first three quarters of 2024, marking a year-on-year increase of 10.03%, and a net profit of 152 million yuan, up 13.06% year-on-year, indicating a successful transformation towards a more efficient operational model [1] Group 1: Financial Performance - For the first three quarters of 2024, Neusoft Group achieved an operating income of 6.891 billion yuan, a year-on-year growth of 10.03% [1] - The net profit for the same period was 152 million yuan, reflecting a year-on-year increase of 13.06% [1] - The non-recurring net profit reached 95.4235 million yuan, showing a significant year-on-year growth of 85.09% [1] Group 2: Strategic Initiatives - Neusoft Group has completed a transformation towards a simpler and more efficient operational model, focusing on intelligent solutions and data value realization [1] - The company has signed new contracts and maintained a growing backlog of orders, with a main business net profit of 298 million yuan [1] - Neusoft Group is actively engaging in strategic collaborations with various provinces and cities to enhance data value in healthcare and smart city initiatives [2] Group 3: Product Development and Innovation - The company has launched several innovative products in 2024, including solutions for county-level medical communities and a global vehicle intelligence travel solution [2] - Neusoft Group introduced multiple intelligent solutions at a recent forum, targeting urban infrastructure and value creation through AI and big data technologies [3] - The company has initiated a high-end hospital clinical specialty data value project and has signed contracts with several top hospitals [2] Group 4: Strategic Investment - A strategic investment agreement was signed between Neusoft Medical and a state-owned enterprise, marking a significant collaboration in the medical imaging equipment sector [3] - The investment process was notably efficient, taking only 173 days from negotiation to signing, and 60 days from signing to completion [3] - Neusoft Medical aims for an IPO in the near future, with plans to start the listing application process next year [3][4]